{"id":"placebo-for-ocrelizumab","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo is an inert substance used as a control in clinical trials to establish the efficacy of an active drug by comparison. Any observed effects in placebo groups are attributed to the placebo effect (psychological and contextual factors) rather than direct drug action. Placebos are essential for blinded trial designs to isolate the true therapeutic benefit of the investigational agent.","oneSentence":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:42:10.026Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in clinical trials for Ocrelizumab (multiple sclerosis)"}]},"trialDetails":[{"nctId":"NCT05285891","phase":"PHASE4","title":"Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-01-12","conditions":"Multiple Sclerosis","enrollment":123},{"nctId":"NCT04035005","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2019-08-12","conditions":"Multiple Sclerosis, Primary Progressive","enrollment":1013},{"nctId":"NCT04877457","phase":"PHASE4","title":"Ocrelizumab for Preventing Clinical Multiple Sclerosis in Individuals With Radiologically Isolated Disease.","status":"TERMINATED","sponsor":"Yale University","startDate":"2022-02-15","conditions":"Radiologically Isolated Syndrome, Multiple Sclerosis","enrollment":3},{"nctId":"NCT01412333","phase":"PHASE3","title":"A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-09-20","conditions":"Relapsing Multiple Sclerosis","enrollment":835},{"nctId":"NCT01247324","phase":"PHASE3","title":"A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-08-31","conditions":"Relapsing Multiple Sclerosis","enrollment":821},{"nctId":"NCT03971487","phase":"PHASE1, PHASE2","title":"Ocrelizumab for Psychosis by Autoimmunity","status":"UNKNOWN","sponsor":"The Methodist Hospital Research Institute","startDate":"2019-10-01","conditions":"Schizo-Affective Type of Psychosis, Schizophrenia","enrollment":40},{"nctId":"NCT01194570","phase":"PHASE3","title":"A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-03-02","conditions":"Multiple Sclerosis, Primary Progressive","enrollment":735},{"nctId":"NCT05779449","phase":"NA","title":"Targeting the Gut Dysbiosis to Treat Inflammation-driven Synaptopathy in MS","status":"RECRUITING","sponsor":"Neuromed IRCCS","startDate":"2023-07-26","conditions":"Patient Participation","enrollment":100},{"nctId":"NCT04880577","phase":"PHASE2","title":"Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple Sclerosis","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2022-09-15","conditions":"Multiple Sclerosis, Relapsing-Remitting, Fatigue","enrollment":""},{"nctId":"NCT00626197","phase":"PHASE3","title":"A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG)","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2008-02-15","conditions":"Lupus Nephritis, Systemic Lupus Erythematosus","enrollment":381}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":79,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Placebo for Ocrelizumab","genericName":"Placebo for Ocrelizumab","companyName":"National Institute of Allergy and Infectious Diseases (NIAID)","companyId":"national-institute-of-allergy-and-infectious-diseases-niaid","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect. Used for Control arm in clinical trials for Ocrelizumab (multiple sclerosis).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}